Table 3.
Demographic, clinical and pathologic characteristics of 280 participants by LB stage
| Characteristics | LB Pathology | p-value | |||
|---|---|---|---|---|---|
| Not
present n=179 |
Stage 1 n=14 |
Stage 2 n= 40 |
Stage 3 n=47 |
||
| Age at death, y, mean (SD) | 91.3 (6.2) | 89.5 (6.4) | 90.0 (6.2) | 90.8 (6.0) | 0.494 † |
| Female, n (%) | 139 (77.7) | 10 (71.4) | 30 (75.0) | 33 (70.2) | 0.731 |
| Education, mean (SD) | 14.5 (3.0) | 15.2 (2.4) | 14.3 (3.2) | 14.9 (2.9) | 0.647 † |
| Odor test score*, mean (SD) | 8.0 (2.4) | 6.8 (2.9) | 7.3 (2.7) | 4.9 (2.8) | <0.001 |
| No cognitive impairment**, n (%) | 75 (41.9) | 4 (28.6) | 13 (32.5) | 11 (23.4) | 0.032 |
| Mild cognitive impairment**, n (%) | 48 (26.8) | 2 (14.3) | 10 (25.0) | 9 (19.2) | |
| Dementia*, n (%) | 56 (31.3) | 8 (57.1) | 17 (42.5) | 27 (57.5) | |
| MMSE score*, mean (SD) | 22.2 (8.5) | 20.8 (6.9) | 18.8 (11.3) | 18.2 (10.2) | 0.029 † |
| Global cognition score*, mean (SD) | −0.56 (0.9) | −1.0 (0.9) | −0.91 (1.3) | −1.06 (1.2) | 0.017 † |
| Global parkinsonism summary score*, mean (SD) | 14.1 (9.4) | 13.5 (8.5) | 12.3 (8.5) | 15.1 (11.3) | 0.748 † |
| Substantia nigra neuronal loss (mild-severe), n (%) | 56 (31.2) | 3 (21.4) | 18 (45.0) | 38 (80.9) | <0.001 |
| Alzheimer’s Disease (NIA-Reagan), n (%) | 132 (73.7) | 7 (50.0) | 31 (77.5) | 34 (72.3) | 0.240 |
*
Last valid odor test score
**
These values were obtained at the time of the last valid odor test.
p-value derived from ANOVA† or chi-square.